|
|
|
|
|
|
|
Materials Science & Biopharmaceutics Joint Meeting
Characterising
Bioperformance of small molecules – new tools and technologies |
|
21st - 22nd May 2009,
Burleigh Court, Loughborough University, Loughborough, UK |
|
|
|
Programme:
[Thursday]
[Friday]
|
|
Thursday
21st May - Day One – ‘Materials testing to inform biopharmaceutics' |
|
9.30 |
|
Coffee and
Registration |
|
|
10.00 |
|
Welcome and
Introduction |
|
|
10.10 |
|
Plenary speaker –
emerging technologies for API and drug product characterization and the
link to bioperformance
Thomas Rades
- School of Pharmacy, University of Otago, NZ |
|
|
10.50 |
|
Salt Selection:
formulation considerations
Barbara Conway, School of Life and Health Sciences – University
of Aston |
|
|
11.30 |
|
Polymorph –
Assessment of Biopharmaceutics risk
Neil Feeder,
Pfizer |
|
12.10 |
|
Lunch and poster
session |
|
13.40 |
|
Biopharmaceutics
risks with salt selection
Gorkhn Sharma
Singh, AstraZeneca |
|
|
14.20 |
|
Short talks (3 x 20
mins) selected from submitted abstracts
|
|
15.20 |
|
Coffee |
|
15.50 |
|
Use of
spectroscopic mapping and imaging in drug product characterisation
Don Clark,
Pfizer |
|
|
16.30 |
|
Improved
understanding of the mechanistic behaviour of MR dosage forms and the
role of low field MRI imaging
James Butler,
GSK |
|
17.10 |
|
Poster Prize
Presentation / Close |
|
|
18.30 |
|
Drinks Reception
and dinner for all Speakers and Delegates |
|
| |
|
|
|
Friday
22nd May - Day Two– ‘Biopharmaceutical performance of characterised
systems’ |
| 09.00 |
|
Current challenges
in predicting bioperformance of complex products
Professor
Christos Reppas, University of Athens |
|
|
09.45 |
|
Amorphous form case
study
Hannah
Batchelor, AstraZeneca |
| 10.30 |
|
Coffee |
|
11.00 |
|
Using Material
Science to Predict Bioperformance - an MSD Case Study
Richard
Kendall, MSD |
|
|
11.45 |
|
QbD, dose form
development and biopharmaceutics
Chris
Davison, GSK |
|
12.30 |
|
Lunch & poster
session |
|
14.00 |
|
Novel dissolution
systems for predicting bioperformance – current experience with the TNO
TIM-1 system
Susann
Bellmann, TNO |
|
|
14.45 |
|
Novel dissolution
systems for predicting bioperformance – the importance of physical
attributes for product performance
Professor
Werner Weitschies, University of Greifswald |
|
|
15.30 |
|
Formulation of
poorly water soluble compounds in early drug development
Chris Towler,
Novartis |
|
|
16.15 |
|
Close of conference |
|
| |
|
BACK TO EVENT OPTIONS |
|
|
